Announcements Trials
Browse Landscape

Phase

Phase 2 83Phase 3 44Phase 1/2 20Phase 1 20Phase EARLY_PHASE1 2

Status

Withdrawn 3Completed 3Terminated 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Hydronephrosis 1

Interventions

pembrolizumab 8Nivolumab 7Magnetic Resonance Spectroscopy 7Radiotherapy 6Biopsy 4Temozolomide 3Specimen Handling 3Irinotecan 3Ipilimumab 3Fluorodeoxyglucose F18 3Dexamethasone 3Bevacizumab 3venetoclax 2niraparib 2gallium 68 PSMA-11 2durvalumab 2avelumab 2Tobacco Use Cessation Devices 2Standard of Care 2Rituximab 2Positron-Emission Tomography 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Neoadjuvant Therapy 2Metastasectomy 2Immunoglobulin G 2FAPI-46 2Disulfides 2Cyclophosphamide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Active not recruiting × durvalumab × Clear all
NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
54 enrolled

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT03215095 2025-07-17

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
11 enrolled 6 charts
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡